Deep Value: cash covers more than 100% of the stock price

This company holds roughly $15M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Marker Therapeutics

MRKR

Biotechnology · Healthcare

Price

$1.12

+0.00 (+0.00%)

Market Cap

$12.1M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+100.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.7M (2021) → 15.3M (2025)

Marker Therapeutics is a small biotech company focused on developing cancer treatments. It works on a type of therapy called multi-tumor associated antigen T-cell therapy, which uses a patient's own immune cells to fight cancer. The company's main focus is on blood cancers like acute myeloid leukemia (AML) and solid tumors, and its potential customers would be cancer patients and hospitals.

The company does not yet sell any approved products, so it earns little to no revenue. It funds its research through equity offerings and grants, which is common for early-stage biotechs. Marker operates primarily in the United States and is very small, with a market cap near zero. Its financial metrics show deep losses, which reflects how much it spends on clinical trials relative to what it earns. The biggest risk is whether its experimental therapies will succeed in clinical trials and eventually win regulatory approval — without that, the company faces serious challenges to its survival.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+60.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$12M/ year

↓ Declining (-12% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

3.8%ownership

Relatively low insider ownership

Cash Runway

~3 years

$15M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$15M cash & investments at current burn rate

Revenue declining

Marker Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-29.5%

Weak — -29.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-63.2%

Shrinking sales (-63.2% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-378.1%

Burning cash (-378.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial